Potential Application of Mesenchymal Stem Cells in Acute Lung Injury
Scientists have been struggling to develop effective treatment options for acute lung injury, a condition with a mortality rate of approximately 40%. Despite extensive research into the pathogenesis of acute lung injury and the acute respiratory distress syndrome, current treatment is primarily supportive. Innovative therapies are needed, and recent studies suggest that bone-marrow-derived multipotent mesenchymal stem cells (MSC) may have therapeutic applications in this area.
Key Takeaways:
- The mortality rate of acute lung injury remains high at approximately 40%, highlighting the need for innovative treatments.
- Current treatment is primarily supportive, with lung-protective ventilation and a fluid conservative strategy, but is not effective in reducing the severity of lung injury.
- Mesenchymal stem cells (MSC) have been studied in several in vivo models of lung disease, with potential therapeutic applications in multiple clinical disorders.
- MSC have been shown to have paracrine effects, releasing soluble factors that promote tissue repair and reduce inflammation.
- The review concludes that future research directions are required to bring MSC therapy to clinical trials.
- Names mentioned include J.W. Lee and colleagues from the University of California.
Statistics:
- Mortality rate of acute lung injury: 40% (approximately)
- Number of studies on MSC therapy: several in vivo models of lung disease
- Potential therapeutic applications of MSC: multiple clinical disorders, including myocardial infarction, diabetes, and sepsis
- Number of studies on paracrine effects of MSC: several
- Percentage of MSC that are bone-marrow-derived: multipotent
Sources:
- Expert Opinion On Biological Therapy (2009;9(10):1259-70)
- Stem Cell Research (no specific date mentioned)
- University of California (no specific date mentioned)
- J.W. Lee, Anesthesiology, University of California (must be contacted for additional information)